STOCK TITAN

Regeneron (REGN) files Form 144 to resell 400 shares via J.P. Morgan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Regeneron Pharmaceuticals filed a Form 144 notice for the proposed sale of 400 shares of Common Stock through J.P. Morgan Securities LLC at its New York address. The filing also records a prior sale of 100 shares on 05/01/2026 for $70,523.79.

Positive

  • None.

Negative

  • None.

Insights

Routine affiliate resale notice for a small quantity of shares.

The filing is a Form 144 disclosure that lists 400 shares of Common Stock to be sold through J.P. Morgan Securities LLC. It also documents a prior sale of 100 shares on 05/01/2026 for $70,523.79.

Regulatory treatment is procedural: Form 144 notifies the market of an affiliate's intent to sell under exemptions. Timing, methods of sale, and net proceeds are not specified in the excerpt.

Shares proposed for resale 400 shares Form 144 listing via J.P. Morgan Securities LLC
Prior sale 100 shares Sold on 05/01/2026
Value of prior sale $70,523.79 Proceeds reported for 100-share sale on 05/01/2026
Form 144 regulatory
"144: Securities To Be Sold Common Stock"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Compensation financial
"Common Stock | 08/22/2013 | Compensation | Issuer"
Securities Sold During The Past 3 Months regulatory
"144: Securities Sold During The Past 3 Months Arthur F. Ryan"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the REGN Form 144 disclose?

It discloses a proposed resale of 400 shares of Regeneron common stock via J.P. Morgan and records a prior sale of 100 shares on 05/01/2026 for $70,523.79. This is a regulatory notice by an affiliate.

Who is the broker handling the proposed sale in the REGN filing?

J.P. Morgan Securities LLC at 270 Park Avenue, New York, is listed as the broker for the 400-share resale. The filing provides the broker's address and identifies the broker as the intermediary for the proposed transaction.

How many shares were previously sold by the reporting person?

The filing shows a prior sale of 100 shares by Arthur F. Ryan on 05/01/2026 with a reported transaction value of $70,523.79. That prior sale is recorded in the "Securities Sold During The Past 3 Months" section.

Does the Form 144 state how proceeds will be used?

The excerpt does not state use of proceeds. The filing lists the number of shares and broker but does not disclose proceeds allocation, timing, or specific sale mechanics in the provided text.